ProMuc was founded to develop synthetic mucins, focusing on lubrication and antimicrobial applications. The company combines Professor Katharina Ribbeck's mucin biology expertise at MIT with carbohydrate chemistry technology from Corden Pharma. The press release cites potential commercial uses including lubricants, food additives, anti-microbial coatings, and anti-cancer vaccines. Harris & Harris Group established ProMuc and provided an initial investment of $350,001. The announcement highlights the role of mucins and the mucus-associated microbiome as a path to advances in health and nutrition industries. The press release did not disclose operating metrics such as revenue or user numbers.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2014